new_0222_0487|VOR|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0487|VOR|1|Vor Biopharma Inc Total Current Assets (Quarterly) (USD)|Vor Biopharma Inc Cash and Short Term Investments (Quarterly) (USD)|Vor Biopharma Inc Inventories (Quarterly) (USD)|Vor Biopharma Inc Net PP&E (Quarterly) (USD)|Vor Biopharma Inc Goodwill and Intangibles (Quarterly) (USD)|Vor Biopharma Inc Total Liabilities (Quarterly) (USD)|Vor Biopharma Inc Total Current Liabilities (Quarterly) (USD)|Vor Biopharma Inc Total Long Term Liabilities (Quarterly) (USD)|Vor Biopharma Inc Total Deposits (Quarterly) (USD)|Vor Biopharma Inc Book Value (Quarterly) (USD)|Vor Biopharma Inc Retained Earnings (Quarterly) (USD)|Vor Biopharma Inc Treasury Stock (Quarterly) (USD)|Vor Biopharma Inc EV to Revenues|Vor Biopharma Inc EV to Earnings|Vor Biopharma Inc EV to Free Cash Flow|Vor Biopharma Inc EV to Assets (Quarterly)|Vor Biopharma Inc PS Ratio|Vor Biopharma Inc PE Ratio|Vor Biopharma Inc Price to Book Value|Vor Biopharma Inc PEG Ratio|Vor Biopharma Inc Debt to Equity Ratio|Vor Biopharma Inc Dividend Yield|Vor Biopharma Inc Shareholder Yield (TTM)|Vor Biopharma Inc Percent of Shares Outstanding Short|Vor Biopharma Inc Total Receivables (Quarterly) (USD)|Vor Biopharma Inc Total Payables (Quarterly) (USD)|Vor Biopharma Inc Total Capital Stock (Quarterly) (USD)|Vor Biopharma Inc Return on Invested Capital|Vor Biopharma Inc Quality Ratio Score|Vor Biopharma Inc Momentum Score|Vor Biopharma Inc Beta (1Y)|Vor Biopharma Inc Sustainable Growth Rate (TTM)|Vor Biopharma Inc Institutional Investor Ownership Percentage|Vor Biopharma Inc Average Diluted Shares Outstanding (Quarterly)|Vor Biopharma Inc Total Employees (Annual)|Vor Biopharma Inc EPS Diluted (Quarterly) (USD)|Vor Biopharma Inc SG&A Expense (Quarterly) (USD)|Vor Biopharma Inc Shares Outstanding|Vor Biopharma Inc Repurchase of Capital Stock (Quarterly) (USD)|Vor Biopharma Inc Ordinary Shares Number (Quarterly)|Vor Biopharma Inc Payout Ratio|Vor Biopharma Inc Quick Ratio (Quarterly)|Vor Biopharma Inc Normalized Diluted EPS (Quarterly) (USD)|Vor Biopharma Inc Stock Buybacks (Quarterly) (USD)|Vor Biopharma Inc Effective Tax Rate (TTM)|Vor Biopharma Inc Return on Equity|Vor Biopharma Inc Net Income (TTM) (USD)|Vor Biopharma Inc Revenue (TTM) (USD)|Vor Biopharma Inc Dividend Per Share (Quarterly) (USD)|Vor Biopharma Inc Revenue (Quarterly) (USD)|Vor Biopharma Inc Gross Profit (Quarterly) (USD)|Vor Biopharma Inc Pre-Tax Income (Quarterly) (USD)|Vor Biopharma Inc Net Income (Quarterly) (USD)|Vor Biopharma Inc Net Interest Income (Quarterly) (USD)|Vor Biopharma Inc Price (USD)|Vor Biopharma Inc Total Return Price (USD)|Vor Biopharma Inc Enterprise Value (USD)|Vor Biopharma Inc 30-Day Average Daily Volume|Vor Biopharma Inc 1 Year Price Returns (Daily)|Vor Biopharma Inc Short Interest|Vor Biopharma Inc PE Ratio (Forward)|Vor Biopharma Inc PE Ratio (Forward 1y)|Vor Biopharma Inc PS Ratio (Forward)|Vor Biopharma Inc PS Ratio (Forward 1y)|Vor Biopharma Inc Quarterly EPS Estimates (USD)|Vor Biopharma Inc Quarterly Revenue Estimates (USD)|Vor Biopharma Inc Quarterly EPS Surprise|Vor Biopharma Inc Quarterly Revenue Surprise|Vor Biopharma Inc Quarterly Actual EPS (USD)|Vor Biopharma Inc Quarterly Actual Revenue (USD)|Vor Biopharma Inc Revenue Estimates for Current Fiscal Year (USD)|Vor Biopharma Inc Revenue Estimates for Next Fiscal Year (USD)|Vor Biopharma Inc Price Target (USD)|Vor Biopharma Inc Consensus Recommendation|Vor Biopharma Inc Price Target Num Estimates|Vor Biopharma Inc EPS Estimates for Current Fiscal Year (USD)|Vor Biopharma Inc EPS Estimates for Next Fiscal Year (USD)|Vor Biopharma Inc Research and Development Expense (Quarterly) (USD)|Vor Biopharma Inc Reconciled Depreciation (Quarterly) (USD)|Vor Biopharma Inc Non-Operating Interest Expense (Quarterly) (USD)|Vor Biopharma Inc Land and Improvements (Quarterly) (USD)|Vor Biopharma Inc Buildings and Improvements (Quarterly) (USD)|Vor Biopharma Inc Other Properties (Quarterly) (USD)|Vor Biopharma Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0487|VOR|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0487|VOR|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0487|VOR|5|127.8|127.8||127.8||127.8|127.8|127.8||127.8|127.8||||1.4427480916||||1.44|||1.4427480916||15.347826087||127.8|127.8|||||||91.2857142857|91|91.2857142857|91.2857142857|30.5555555556||127.8|||91.2857142857|91.3333333333|||91.25|||||91.2857142857|91.2857142857|91.2857142857|1.4427480916|1.4427480916|1.4427480916|1.44206008584|1.22222222222|15.347826087|||||91.25|91.25|91.5||91.5|91|43.875|41.4285714286|19.1176470588|14.7727272727|19.1176470588|23.4|20.7142857143|91.2857142857|91.2857142857||||127.8|127.8||
new_0222_0487|VOR|6|5|5||5||5|5|5||5|5||||262||||225|||262||23||5|5|||||||7|3|7|7|9||5|||7|6|||4|||||7|7|7|262|262|262|233|9|23|||||8|8|2||2|3|8|7|17|22|17|15|14|7|7||||5|5||
new_0222_0487|VOR|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0487|VOR|201912|7.539|6.466||0.728||2.186|2.186|||-17.429|-17.887|||||||||||||||0.693|25.069|||||||12.2082||-0.3603|0.964|||34.6414|||-0.3189|||||||||-3.893|-3.893|0.035||||||||||||||||||||||||2.964|0.041||||0.843|0.006||
new_0222_0487|VOR|202003||||||||||||||||||||||||||||||||||12.2082||-0.7015|1.707||||||-0.6429|||||||||-7.849|-7.849|0.029||||||||||||||||||||||||6.171|0.066|||||||
new_0222_0487|VOR|202006||||||||||||||||||||||||||||||||||12.2082||-0.7286|2.065||||||-0.6586|||||||||-8.04|-8.04|||||||||||||||||||||||||5.975|0.105|||||||
new_0222_0487|VOR|202009|65.524|63.604||21.087||25.331|7.6|17.731||-44.142|-45.561|||||||||||||||2.321|107.336|||||||12.2082||-1.1443|3.643|||34.6414|||-0.9653||||-31.567|||||-11.785|-11.785|||||||||||||||||||||||||8.142|0.192||||21.087|||
new_0222_0487|VOR|202012|49.106|48.539||21.845||27.637|10.207|17.43||-59.065|-61.224||||-42.7091|||||||||1.1446||2.361|107.337||||||45.9837|34.6414|76|-0.5148|4.333|37.12||34.6414|||-0.4521||||-43.337|||||-15.663|-15.663||44.96|44.96|1727.7122|||424859|||||-3.335|||||||||||-10.605||11.33|0.242||||22.364|0.207||
new_0222_0487|VOR|202103|266.265|262.567||22.533||25.752|8.631|17.121||267.187|-74.947||||-25.1167||||5.9314|||||3.9706||2.406|0.004|||||||22.264||-0.67|4.789|36.77||36.77|||-0.67|-189.199|||-49.211|||||-13.723|-13.723|0.007|43.1|43.1|1322.22|320345.5||1459990|||||-0.76||11.8421||-0.67||||48.25|1.8|4|-2.76|-2.76|8.941|0.311||||23.354|0.216|28.18|21.1
new_0222_0487|VOR|202106|249.265|244.634||22.208||25.035|8.304|16.731||250.108|-93.317||||-7.2376||||2.7505|||||4.3063||2.369|0.004|||||||36.8431|109|-0.5|5.41|36.8854||36.8854|||-0.5||||-59.541|||||-18.37|-18.37|0.01|18.65|18.65|443.2787|138667.5333||1588383|||||-0.4633||-7.9144||-0.5||||47.75|1.8|4|-2.3067|-2.7033|12.97|0.354||||23.366|0.233|12.52|14.69
new_0222_0487|VOR|202109|232.072|225.968||22.006||25.675|9.21|16.465||232.957|-111.871||||-5.1082||||2.4916|||||4.9734||1.957|0.004|||||||36.9343|122|-0.5|5.677|37.0183||37.0183|||-0.5||||-66.31|||||-18.554|-18.554|0.048|15.68|15.68|354.4789|187490.5667||1841085|||||-0.575||13.0435||-0.5||||51.75|2|4|-2.385|-2.61|12.925|0.374||||23.467|0.302|15.73|11.54
new_0222_0487|VOR|202112|||||||||||||||-2.9878||||1.86|||||4.8097|||||||||||||||||||||||||||||||11.62|11.62|207.336|127450.1667|-79.7792|1793499|||||-0.5367||||||||42.8571|1.4286|7|-2.37|-2.6233||||||||8.25|9.34
new_0222_0487|VOR|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.5775|||||||||||||||||||||
new_0222_0487|VOR|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.6425|||||||||||||||||||||
new_0222_0487|VOR|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.71|||||||||||||||||||||
new_0222_0487|VOR|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.7625|||||||||||||||||||||